Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast
Abstract In recent years, the armamentarium of therapies for the management of advanced renal cell carcinoma (aRCC) has grown. Combination therapies, including immuno-oncology (IO) agents and tyrosine kinase inhibitors [TKIs (IO–TKI)], and IO–IO combinations, are now approved for first-line treatmen...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-10-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-024-00305-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162618035077120 |
|---|---|
| author | Benjamin Garmezy Ulka Vaishampayan |
| author_facet | Benjamin Garmezy Ulka Vaishampayan |
| author_sort | Benjamin Garmezy |
| collection | DOAJ |
| description | Abstract In recent years, the armamentarium of therapies for the management of advanced renal cell carcinoma (aRCC) has grown. Combination therapies, including immuno-oncology (IO) agents and tyrosine kinase inhibitors [TKIs (IO–TKI)], and IO–IO combinations, are now approved for first-line treatment of aRCC. Decisions regarding the use of these combinations, IO–IO versus IO–TKI, can be challenging, as they have not been compared in a randomized trial; each of these combinations have been compared with sunitinib alone. In addition, patient-, disease-, and treatment-based factors must be evaluated in the decision-making process. More important is the consideration of patient management during treatment and optimal detection and management of toxicities to ensure continued benefit. In this vodcast, two experts in the field of kidney cancer will present case studies that represent typical patients seen in practice. The faculty will discuss treatment approaches, adverse event management, and which factors to consider during the treatment decision-making process. Viewers of the vodcast will get a better understanding of clinical trial outcomes related to an IO–TKI combination, such as axitinib plus pembrolizumab, that they can apply to their practice immediately. In addition, they will gain real-world insight into how experts approach the treatment of patients with aRCC and, more importantly, therapy management. |
| format | Article |
| id | doaj-art-da00f9f32c5241088dd07e9cc433701f |
| institution | OA Journals |
| issn | 2366-1070 2366-1089 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Oncology and Therapy |
| spelling | doaj-art-da00f9f32c5241088dd07e9cc433701f2025-08-20T02:22:30ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892024-10-0112464766110.1007/s40487-024-00305-3Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A VodcastBenjamin Garmezy0Ulka Vaishampayan1Sarah Cannon Research InstituteDepartment of Medicine/Oncology, University of MichiganAbstract In recent years, the armamentarium of therapies for the management of advanced renal cell carcinoma (aRCC) has grown. Combination therapies, including immuno-oncology (IO) agents and tyrosine kinase inhibitors [TKIs (IO–TKI)], and IO–IO combinations, are now approved for first-line treatment of aRCC. Decisions regarding the use of these combinations, IO–IO versus IO–TKI, can be challenging, as they have not been compared in a randomized trial; each of these combinations have been compared with sunitinib alone. In addition, patient-, disease-, and treatment-based factors must be evaluated in the decision-making process. More important is the consideration of patient management during treatment and optimal detection and management of toxicities to ensure continued benefit. In this vodcast, two experts in the field of kidney cancer will present case studies that represent typical patients seen in practice. The faculty will discuss treatment approaches, adverse event management, and which factors to consider during the treatment decision-making process. Viewers of the vodcast will get a better understanding of clinical trial outcomes related to an IO–TKI combination, such as axitinib plus pembrolizumab, that they can apply to their practice immediately. In addition, they will gain real-world insight into how experts approach the treatment of patients with aRCC and, more importantly, therapy management.https://doi.org/10.1007/s40487-024-00305-3Renal cell carcinomaAxitinibPembrolizumabSunitinibTreatment management |
| spellingShingle | Benjamin Garmezy Ulka Vaishampayan Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast Oncology and Therapy Renal cell carcinoma Axitinib Pembrolizumab Sunitinib Treatment management |
| title | Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast |
| title_full | Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast |
| title_fullStr | Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast |
| title_full_unstemmed | Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast |
| title_short | Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast |
| title_sort | understanding treatment decisions and management for patients with advanced renal cell carcinoma using hypothetical case studies a vodcast |
| topic | Renal cell carcinoma Axitinib Pembrolizumab Sunitinib Treatment management |
| url | https://doi.org/10.1007/s40487-024-00305-3 |
| work_keys_str_mv | AT benjamingarmezy understandingtreatmentdecisionsandmanagementforpatientswithadvancedrenalcellcarcinomausinghypotheticalcasestudiesavodcast AT ulkavaishampayan understandingtreatmentdecisionsandmanagementforpatientswithadvancedrenalcellcarcinomausinghypotheticalcasestudiesavodcast |